SCHEMBL1103628

SCHEMBL1103628

c1ccc(-c2c3ccc(-c4ccc5ccccc5c4)cc3c(-c3ccccc3)c3ccncc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 5/20 0.55
CYP11B1 P15538 4/20 0.55
CYP19A1 P11511 3/20 0.55
CYP17A1 P05093 3/20 0.55
MAPK10 P53779 4/20 0.43
TNF P01375 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
CCNC P24863 2/20 0.41
CDK8 P49336 2/20 0.41
HSD17B1 P14061 2/20 0.41
HSD17B2 P37059 2/20 0.41
MAPK9 P45984 3/20 0.40
SIRT2 Q8IXJ6 3/20 0.40
MAPK8 P45983 2/20 0.40
PRKCZ Q05513 1/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103672 0.99 CYP11B2 (0.54) CYP11B2CYP11B1CYP19A1CYP17A1MAPK10
SCHEMBL1103625 0.99 CYP11B2 (0.54) CYP11B2CYP11B1CYP19A1CYP17A1MAPK10
SCHEMBL1103660 0.97 CYP11B2 (0.53) CYP11B2CYP11B1CYP19A1CYP17A1MAPK10
SCHEMBL1103662 0.97 CYP11B2 (0.53) CYP11B2CYP11B1CYP19A1CYP17A1MAPK10
SCHEMBL1103661 0.97 CYP11B2 (0.53) CYP11B2CYP11B1CYP19A1CYP17A1MAPK10
SCHEMBL1103675 0.97 CYP11B2 (0.53) CYP11B2CYP11B1CYP19A1CYP17A1MAPK10
SCHEMBL1103686 0.97 CYP11B2 (0.53) CYP11B2CYP11B1CYP19A1CYP17A1MAPK10
SCHEMBL1103684 0.96 CYP11B2 (0.51) CYP11B2CYP11B1CYP19A1CYP17A1MAPK10
SCHEMBL1103692 0.96 CYP11B2 (0.51) CYP11B2CYP11B1CYP19A1CYP17A1MAPK10
SCHEMBL1103647 0.96 CYP11B1 (0.50) CYP11B2CYP11B1CYP19A1CYP17A1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 CYP11B2 652/4885CYP11B1 836/4885CYP19A1 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.